Tocilizumab to prevent lung transplant rejection
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be listed for or have already received a lung transplant (not multi-organ).
- You must weigh at least 66 pounds (30 kg).
- You cannot have had desensitization therapy before the transplant.
- You must have had a TB test within the past year and completed treatment if positive.
- You cannot have certain infections like HIV, active hepatitis B/C, or specific lung infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called emapalumab can help lung transplant recipients whose transplanted lungs are showing signs of rejection. The drug targets a specific immune protein (interferon gamma) that appears to drive this type of rejection.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
Hear when a new Lung Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.